FDA grants Hardy Diagnostics EUA for COVID-19 antibody test
May 5, 2020—Hardy Diagnostics announced FDA EUA approval the Anti-SARS-CoV-2 Rapid Test.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
FDA enforcement discretion now includes Aperio WebViewer
May 4, 2020—Leica Biosystems announced it has received additional notification from the FDA about its intention to exercise enforcement discretion when the Aperio WebViewer, a web-based viewing software within Aperio eSlide Manager
Roche’s COVID-19 antibody test receives EUA
May 4, 2020—Roche announced that the FDA has issued an emergency use authorization for its Elecsys Anti-SARS-CoV-2 antibody test.
Rheonix receives EUA for rapid molecular COVID-19 test
May 1, 2020—Rheonix announced it has received FDA emergency use authorization for the Rheonix COVID-19 MDx Assay.
Hologic to launch second assay for novel coronavirus
April 30, 2020—Hologic plans to launch an Aptima molecular assay to detect the SARS-CoV-2 virus that will run on its Panther system, which provides initial results in about three hours and processes more than 1,000 coronavirus tests in a 24-hour period. The company expects to begin distributing next week a research use only version of its Aptima SARS-CoV-2 test to hospital, public health, and reference laboratories certified under CLIA to perform high-complexity tests and plans to provide its laboratory customers
Ortho launches second COVID-19 antibody test
April 27, 2020—Ortho Clinical Diagnostics announced the FDA granted emergency use authorization to its second COVID-19 antibody test, the Vitros Immunodiagnostic Products Anti-SARS-CoV-2 IgG Test.
FDA approves Cobas HPV test for Cobas 6800/8800 systems
April 24, 2020—Roche announced FDA approval for the Cobas HPV test for use on the fully automated, high-throughput Cobas 6800/8800 systems.
ELITechGroup MDx distributes EUA kit
April 23, 2020—ELITechGroup MDx and its Korean partner, Osang Healthcare, announced that the FDA has issued emergency use authorization for its SARS-CoV-2 virus test for use in the United States.
Randox unveils molecular controls for SARS-CoV-2
April 23, 2020—Randox Laboratories has developed Randox Qnostics SARS-CoV-2 whole pathogen quality controls designed for laboratories managing COVID-19 testing to help ensure the accuracy and reliability of molecular assays used in the testing of suspected coronavirus samples.
FDA clears i-Stat CG4+, Chem8+
April 22, 2020—Abbott’s i-Stat CG4+ and Chem8+ cartridges have received FDA clearance.